Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321459512> ?p ?o ?g. }
- W4321459512 endingPage "1349" @default.
- W4321459512 startingPage "1349" @default.
- W4321459512 abstract "Novel immune therapies are currently being used for patients with R/R ALL based on their ability to induce not only hematologic but also molecular remission. Despite promising results, specific clinical conditions, such as high tumor burden or extra medullary relapse, are still associated with a remarkably poor clinical outcome. Therefore, how to optimize the choice and the timing of such new treatments within different clinical settings remains a matter of debate. In addition, with the aim of increasing the rate and depth of molecular remission, clinical studies are currently evaluating the combination of these immunotherapies with chemotherapy in the contest of frontline treatment. The preliminary data suggest that this approach may increase the cure rate and perhaps reduce the use of allogeneic stem cell transplantation (alloHSCT) in first remission. In Ph-positive ALL, reproducible results are showing that frontline treatment programs, based on the combination of tyrosine kinase inhibitors and immunotherapy, can achieve unprecedented rates of hematologic and molecular remission as well as a long-term cure, even in the absence of chemotherapy and alloHSCT. The results from these studies have led to the development of potentially curative treatment modalities, even for older ALL patients who cannot be treated with conventional intensive chemotherapy. The present review examined the evidence for an appropriate use of the new immunotherapies in ALL patients and provided some appraisal of the current and future possible uses of these drugs for achieving further therapeutic improvement in the treatment of this disease." @default.
- W4321459512 created "2023-02-22" @default.
- W4321459512 creator A5025946232 @default.
- W4321459512 creator A5050990109 @default.
- W4321459512 creator A5053685451 @default.
- W4321459512 creator A5055401685 @default.
- W4321459512 date "2023-02-20" @default.
- W4321459512 modified "2023-09-26" @default.
- W4321459512 title "Optimal Use of Novel Immunotherapeutics in B-Cell Precursor ALL" @default.
- W4321459512 cites W1555553634 @default.
- W4321459512 cites W1967512987 @default.
- W4321459512 cites W2065851457 @default.
- W4321459512 cites W2087090648 @default.
- W4321459512 cites W2107925822 @default.
- W4321459512 cites W2118796952 @default.
- W4321459512 cites W2129702476 @default.
- W4321459512 cites W2135363598 @default.
- W4321459512 cites W2179454156 @default.
- W4321459512 cites W2400439118 @default.
- W4321459512 cites W2419639370 @default.
- W4321459512 cites W2496398835 @default.
- W4321459512 cites W2507805157 @default.
- W4321459512 cites W2527615464 @default.
- W4321459512 cites W2539686048 @default.
- W4321459512 cites W2582784681 @default.
- W4321459512 cites W2591709377 @default.
- W4321459512 cites W2599899418 @default.
- W4321459512 cites W2609835530 @default.
- W4321459512 cites W2614019261 @default.
- W4321459512 cites W2653911491 @default.
- W4321459512 cites W2787145330 @default.
- W4321459512 cites W2787301955 @default.
- W4321459512 cites W2787621143 @default.
- W4321459512 cites W2804546534 @default.
- W4321459512 cites W2807514643 @default.
- W4321459512 cites W2888107969 @default.
- W4321459512 cites W2892132284 @default.
- W4321459512 cites W2892758519 @default.
- W4321459512 cites W2893691711 @default.
- W4321459512 cites W2896845000 @default.
- W4321459512 cites W2907699286 @default.
- W4321459512 cites W2911504656 @default.
- W4321459512 cites W2913949832 @default.
- W4321459512 cites W2914373601 @default.
- W4321459512 cites W2916249195 @default.
- W4321459512 cites W2922798588 @default.
- W4321459512 cites W2931981435 @default.
- W4321459512 cites W2936395380 @default.
- W4321459512 cites W2942381021 @default.
- W4321459512 cites W2962839079 @default.
- W4321459512 cites W2969454127 @default.
- W4321459512 cites W2971361007 @default.
- W4321459512 cites W2972280750 @default.
- W4321459512 cites W2981307194 @default.
- W4321459512 cites W2984670758 @default.
- W4321459512 cites W2986316381 @default.
- W4321459512 cites W2987238843 @default.
- W4321459512 cites W2989508673 @default.
- W4321459512 cites W2990115538 @default.
- W4321459512 cites W2992270245 @default.
- W4321459512 cites W2992389962 @default.
- W4321459512 cites W2997778794 @default.
- W4321459512 cites W3001143067 @default.
- W4321459512 cites W3004611567 @default.
- W4321459512 cites W3005187572 @default.
- W4321459512 cites W3015637769 @default.
- W4321459512 cites W3025865156 @default.
- W4321459512 cites W3030234447 @default.
- W4321459512 cites W3048352978 @default.
- W4321459512 cites W3048920163 @default.
- W4321459512 cites W3083588228 @default.
- W4321459512 cites W3093938683 @default.
- W4321459512 cites W3095855647 @default.
- W4321459512 cites W3095861981 @default.
- W4321459512 cites W3097066934 @default.
- W4321459512 cites W3109133697 @default.
- W4321459512 cites W3122867248 @default.
- W4321459512 cites W3126166324 @default.
- W4321459512 cites W3133430707 @default.
- W4321459512 cites W3134763925 @default.
- W4321459512 cites W3135688349 @default.
- W4321459512 cites W3137871084 @default.
- W4321459512 cites W3138004978 @default.
- W4321459512 cites W3169193862 @default.
- W4321459512 cites W3185353197 @default.
- W4321459512 cites W3196943407 @default.
- W4321459512 cites W3203800488 @default.
- W4321459512 cites W3205544897 @default.
- W4321459512 cites W3207132694 @default.
- W4321459512 cites W3216856495 @default.
- W4321459512 cites W4200374302 @default.
- W4321459512 cites W4200571298 @default.
- W4321459512 cites W4206401256 @default.
- W4321459512 cites W4206742881 @default.
- W4321459512 cites W4213086572 @default.
- W4321459512 cites W4213165752 @default.
- W4321459512 cites W4220653161 @default.
- W4321459512 cites W4220685620 @default.